UBS Group
RNA

UBS Group’s Atrium Therapeutics RNA Stock Holding History

UBS Group’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Sell
19,572
-30,242
-61% -$395K ﹤0.01% 6641
2026
Q1 		$666K Buy
+49,814
New +$700K ﹤0.01% 5858

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

UBS Group's RNA Position: Q2 2026 in Review

UBS Group reduced its Atrium Therapeutics (RNA) stake by 61% in Q2 2026, selling an estimated $395K and leaving 19,572 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #6641.

UBS Group first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. The position peaked at $666K in Q1 2026. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • UBS Group held 19,572 shares of Atrium Therapeutics worth $263K as of Q2 2026.
  • UBS Group sold 30,242 Atrium Therapeutics shares in Q2 2026, an estimated $395K.
  • Atrium Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6641 holding.
  • UBS Group first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • UBS Group's Atrium Therapeutics position peaked at $666K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.